Abstract
Gene-directed enzyme prodrug therapy involves tumor-specific delivery of a gene encoding a drug-metabolizing enzyme allowing metabolism of a non-toxic prodrug to a toxic species directly within tumor cells. This review covers the wide range of enzyme-prodrug combinations currently under preclinical and clinical investigation. Issues of tumor specificity and enhanced cytotoxicity through bystander effects will be discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 421-435 |
| Journal | Current Opinion in Molecular Therapeutics |
| Volume | 6 |
| Issue number | 4 |
| Publication status | Published (in print/issue) - Aug 2004 |